Brief: Ascentage Pharma Group International Says Loss For Year Up 12.8% To RMB882.9 Million
22/03/2023 15:31
March 22 (Reuters) - Ascentage Pharma Group
International 6855.HK :
* LOSS FOR YEAR INCREASED BY 12.8% TO RMB882.9 MILLION
* REVENUE FOR YEAR RMB209.7 MILLION, INCREASE OF 651.6%
* SEES TO EXPAND INTELLECTUAL PROPERTY PORTFOLIO BY ACTIVELY
SEEKING PATENT RIGHTS FOR PRODUCT CANDIDATES
Source text for Eikon: ID:nHKS5gB8YZ
Further company coverage: 6855.HK
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up